Phase 1 clinical trial results indicate Harm Reduction Therapeutics LLC's proposed RiVive OTC naloxone nasal spray has biological results comparable to Rx intramuscular naloxone available in the US.
The trial of the 3-mg nasal spray, identified in HRT's study as HRT001, which delivers an atomized form of 0.1-mL...







